CARLSBAD, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Little Rock, Arkansas laboratory based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
The facility's director, David N. Pope, MD, was advised of this national recognition and congratulated for the excellence of the services being provided at the facility. Signal's laboratory is one of more than 7,600 CAP-accredited facilities worldwide.
Sam Riccitelli, Signal's President and CEO, commented, "We are excited to have received accreditation from the College of American Pathologists for our laboratory in Little Rock. This further demonstrates our Company's dedication to providing a quality diagnostic to patients suffering from multiple myeloma, and the physicians who treat them, in order to improve individual care. We believe this also speaks to the talent and commitment of the staff of this lab. This is an exciting time for Signal and we look forward to continuing to work toward our goals of growing the Company and enhancing the treatment of those who suffer from this disease."
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.
About the College of American Pathologists
The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the world's largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care. More information about the CAP can be found at www.cap.org.